Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 128 Enz. Inhib. hit(s) with all data for entry = 1724
TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13662(3-Oxybenzamide 48 | 4-chloro-3-[2-(2,4-dichlorophe...)
Affinity DataKi:  10nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13668(3-Oxybenzamide 54 | 4-chloro-3-[2-(4-chlorophenyl)...)
Affinity DataKi:  13nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13663(3-Oxybenzamide 49 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  13nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13664(3-Oxybenzamide 50 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  18nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMedMMDB
PDB3D3D Structure (crystal)

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13615(3-Oxybenzamide 1 | 4-chloro-3-[2-(5-chloropyridin-...)
Affinity DataKi:  20nM ΔG°:  -43.9kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13659(3-Oxybenzamide 45 | 4-bromo-3-[2-(2,4-dichlorophen...)
Affinity DataKi:  20nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13670(3-Oxybenzamide 56 | 4-chloro-3-[2-(4-chlorophenyl)...)
Affinity DataKi:  25nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13652(3-Oxybenzamide 38 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  28nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13645(3-Oxybenzamide 31 | 4-amino-3-[2-(2,4-dichlorophen...)
Affinity DataKi:  29nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13619(3-Oxybenzamide 5 | 3-[2-(4-bromophenyl)ethoxy]-4-c...)
Affinity DataKi:  36nM ΔG°:  -42.5kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13642(3-Oxybenzamide 28 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  37nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13618(3-Oxybenzamide 4 | 3-[2-(5-chloropyridin-2-yl)etho...)
Affinity DataKi:  37nM ΔG°:  -42.4kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13658(3-Oxybenzamide 44 | 7-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  39nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13617(3-Oxybenzamide 3 | 3-[2-(4-chlorophenyl)ethoxy]-4-...)
Affinity DataKi:  40nM ΔG°:  -42.2kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13665(3-Oxybenzamide 51 | 3-[2-(4-chlorophenyl)ethoxy]-4...)
Affinity DataKi:  41nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13667(3-Oxybenzamide 53 | 4-chloro-3-[2-(2,4-dichlorophe...)
Affinity DataKi:  41nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13644(3-Oxybenzamide 30 | 4-cyano-3-[2-(2,4-dichlorophen...)
Affinity DataKi:  44nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13646(3-Oxybenzamide 32 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  48nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13616(3-Oxybenzamide 2 | 3-[2-(2,4-dichlorophenyl)ethoxy...)
Affinity DataKi:  50nM ΔG°:  -41.7kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13656(3-Oxybenzamide 42 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  50nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13651(3-Oxybenzamide 37 | 5-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  51nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13666(3-Oxybenzamide 52 | 3-[2-(5-chloropyridin-2-yl)eth...)
Affinity DataKi:  54nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13673(3-Oxybenzamide 59 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  57nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13653(3-Oxybenzamide 39 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  61nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13629(3-Oxybenzamide 15 | 3-[2-(4-bromophenyl)ethoxy]-4-...)
Affinity DataKi:  71nM ΔG°:  -40.8kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13647(3-Oxybenzamide 33 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  75nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13640(3-Oxybenzamide 26 | 4-bromo-3-[2-(2,4-dichlorophen...)
Affinity DataKi:  76nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13660(3-Oxybenzamide 46 | 4-bromo-3-[2-(2,4-dichlorophen...)
Affinity DataKi:  86nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13620(3-Oxybenzamide 6 | 4-chloro-3-[2-(4-fluorophenyl)e...)
Affinity DataKi:  102nM ΔG°:  -39.9kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13639(3-Oxybenzamide 25 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  106nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13674(3-Oxybenzamide 60 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  110nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13621(3-Oxybenzamide 7 | 4-chloro-3-[2-(4-methylphenyl)e...)
Affinity DataKi:  124nM ΔG°:  -39.4kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13655(3-Oxybenzamide 41 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  125nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13643(3-Oxybenzamide 29 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  140nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13689(3-Oxybenzamide 75 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  140nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13671((2S)-5-carbamimidamido-2-({3-[2-(2,4-dichloropheny...)
Affinity DataKi:  153nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13641(3-Oxybenzamide 27 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  156nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13706(1-({3-[2-(2,4-dichlorophenyl)ethoxy]-4,5-dimethoxy...)
Affinity DataKi:  167nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13687(3-Oxybenzamide 73 | N-[(1-carbamimidoylpiperidin-4...)
Affinity DataKi:  173nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13672(3-Oxybenzamide 58 | N-[(1-carbamimidoylpiperidin-4...)
Affinity DataKi:  189nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13630(3-Oxybenzamide 16 | 4-fluoro-3-[2-(4-fluorophenyl)...)
Affinity DataKi:  203nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13631(3-Oxybenzamide 17 | 4-fluoro-3-[2-(4-methylphenyl)...)
Affinity DataKi:  206nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13654(3-Oxybenzamide 40 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  233nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13657(3-Oxybenzamide 43 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  263nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13675(3-Oxybenzamide 61 | N-{[1-(2-chloropyrimidin-4-yl)...)
Affinity DataKi:  264nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13669(2-bromo-3-[2-(2,4-dichlorophenyl)ethoxy]-5-({[1-(p...)
Affinity DataKi:  285nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13707(1-({3-[2-(2,4-dichlorophenyl)ethoxy]-4-ethoxypheny...)
Affinity DataKi:  306nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13632(3-Oxybenzamide 18 | 4-fluoro-3-[2-(4-methoxyphenyl...)
Affinity DataKi:  307nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13622(3-Oxybenzamide 8 | 4-chloro-3-[2-(4-methoxyphenyl)...)
Affinity DataKi:  314nM ΔG°:  -37.1kJ/molepH: 7.8 T: 25°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

TargetCoagulation factor X(Human)
Aventis Pharma Deutschland

LigandPNGBDBM13648(3-Oxybenzamide 34 | 3-[2-(2,4-dichlorophenyl)ethox...)
Affinity DataKi:  316nMAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed

Displayed 1 to 50 (of 128 total ) | Next | Last >>
Jump to: